Compare Roivant Sciences Ltd. Common Shares (ROIV) vs Millicom International Cellular S.A. Common Stock (TIGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roivant Sciences Ltd. Common Shares vs Millicom International Cellular S.A. Common Stock — how do they compare? Roivant Sciences Ltd. Common Shares trades at $33.62 (market cap $24.99B), while Millicom International Cellular S.A. Common Stock trades at $80.27 (market cap $13.34B). The key difference: Roivant Sciences Ltd. Common Shares is the larger of the two by market cap, and Millicom International Cellular S.A. Common Stock pays a 3.77% dividend while Roivant Sciences Ltd. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Roivant Sciences Ltd. Common Shares for 3 Days and Millicom International Cellular S.A. Common Stock for 0 Days on average.
| ROIV | TIGO | |
|---|---|---|
Market Cap | $24.99B | $13.34B |
Volume | 4,711,562 | 1,586,684 |
Sector | Health | Media |
52-Week High | $41.81 | $104.31 |
52-Week Low | $16.99 | $45.81 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $21.25B | $24.38B |
Dividend Yield | — | 3.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Roivant Sciences (ROIV) trades at $33.35, down 3.58% on the day amid a bearish technical signal. The stock faces fundamental headwinds with a net loss of $172 million in 2025 and negative cash flow, though recent news highlights pipeline progress including positive Phase 2 data for mosliciguat in PH-ILD. Analyst sentiment remains strongly bullish with a consensus price target of $46.75.
The outlook hinges on clinical execution; upside exists if pipeline assets like LISRAYA launch successfully, but high cash burn and profitability challenges pose significant risks. Near-term price action is pressured, but long-term value depends on converting R&D into commercial success.
TIGO trades at $79.54, down 0.92% on the day, with a neutral technical signal and key support at $79. The company reported strong 2025 results with $5.82B revenue and $1.32B net income, but 2026 earnings have missed expectations in two of the last three quarters. Recent news highlights its addition to Zacks' Strong Buy list and a consistent $0.75 quarterly dividend.
The stock offers a 12.9% upside to the consensus price target of $89.78, supported by solid profitability and cash flow, but faces risks from earnings volatility and high debt. Analyst sentiment is mixed with a Hold consensus, suggesting cautious optimism amid integration challenges from recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Roivant Sciences Ltd. Common Shares
Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →About Millicom International Cellular S.A. Common Stock
Millicom International Cellular S.A. operates telecommunications and digital services under the Tigo brand across Latin America, providing mobile, fiber broadband, and pay-TV services. The company also offers mobile financial services through its Tigo Money business.
Read more on TIGO →
